Heather Wieffer leads and advises on projects across global market access, bringing broad and deep knowledge of health technology assessment (HTA), pricing, and value demonstration in global markets.
She has over 15 years’ experience in market access consultancy across landscape assessment and strategy, primary and secondary research, and bespoke evidence generation. Recent project examples include evaluation of inpatient drug funding pathways, HTA insight generation, and facilitation of a European advisory board to support portfolio-level evidence generation and policy activities.
Heather holds a PhD in immunology from the University of Vienna and a postgraduate diploma in health economics from the University of York.
Authored Content
Healthcare decisionmakers are increasingly considering evaluation of environmental impact; Avalere Health research explores the implications for manufacturers.
Increasing interplay between US and ex-US drug pricing requires manufacturers to shift to a truly globalized model to future-proof their access strategies.
With global market access teams navigating a rapidly changing environment, there are several key concepts reshaping how access teams think, plan, and operate to deliver real-word patient access.